- CA$11.52m
- CA$22.72m
- CA$48.80m
- 38
- 75
- 53
- 55
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.8 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.24 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -79.93% | ||
| Return on Equity | -51.17% | ||
| Operating Margin | -26.21% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | 15.89 | 34.05 | 54.34 | 48.8 | 46.3 | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
IM Cannabis Corp. is a Canada-based medical cannabis company. The Company operates in Israel through its commercial relationship with Focus Medical Herbs Ltd. (Focus Medical), which has a cultivation license to breed, grow and supply medical cannabis products in Israel. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centres and logistical hubs in Israel. The Company operates through Adjupharm GmbH in Europe, which is a medical cannabis producer and distributor with wholesale, narcotics handling, manufacturing, procurement, storage, and distribution licenses granted by German regulatory authorities that allow for import/export capability with requisite permits. The Company operates through Trichome and its subsidiaries Trichome JWC Acquisition Corp. and MYM Nutraceuticals Inc., where it cultivates and processes cannabis for the adult-use market at its Ontario and Nova Scotia facilities under the WAGNERS and Highland Grow brands.
Directors
- Marc Lustig CHM
- Oren Shuster CEO
- Shai Shemesh CFO
- Richard Balla CEX
- Yael Harrosh COO
- Doron Reznick OTH
- Haleli Barath IND
- Vivian Bercovici IND
- Brian Schinderle IND
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 7th, 1980
- Public Since
- November 5th, 2019
- No. of Employees
- 95
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Canadian Securities Exchange- Shares in Issue
- 13,394,136
- Address
- 1 Adelaide Street East, Unit 801, TORONTO ISLAND, M5C 2V9
- Web
- https://imcannabis.com/
- Phone
- +1 4162564202
- Auditors
- Kost Forer & Gabbay
Upcoming Events for IMCC
Q2 2024 IM Cannabis Corp Earnings Release
Similar to IMCC
1933 Industries
Canadian Securities Exchange
1CM
Canadian Securities Exchange
Acreage Holdings
Canadian Securities Exchange
Adastra Holdings
Canadian Securities Exchange
Aion Therapeutic
Canadian Securities Exchange
FAQ
What is the IM Cannabis share price?
As of Today at 19:11 UTC, shares in IM Cannabis are trading at CA$0.86. This share price information is delayed by 15 minutes.
How has the IM Cannabis share price performed this year?
Shares in IM Cannabis last closed at CA$0.86 and the price had moved by -11.34% over the past 365 days. In terms of relative price strength the IM Cannabis share price has underperformed the Toronto Stock Exchange 300 Composite Index by -16.68% over the past year.
What are the analyst and broker recommendations for IM Cannabis?
The overall consensus recommendation for IM Cannabis is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the IM Cannabis dividend yield?
IM Cannabis does not currently pay a dividend.
Does IM Cannabis pay a dividend?
IM Cannabis does not currently pay a dividend.
When does IM Cannabis next pay dividends?
IM Cannabis does not currently pay a dividend.
How do I buy IM Cannabis shares?
To buy shares in IM Cannabis you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of IM Cannabis?
As of the previous close price of CA$0.86, shares in IM Cannabis had a market capitalisation of CA$11.52m.
Where are IM Cannabis shares listed?
Here are the trading details for IM Cannabis:
- Country of listing: Canada
- Exchange: CNX
- Ticker Symbol: IMCC
What kind of share is IM Cannabis?
Based on an overall assessment of its quality, value and momentum IM Cannabis is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a IM Cannabis share price forecast for 2024?
The analyst consensus target price for shares in IM Cannabis is CA$3.45. That is 301.16% above the last closing price of CA$0.86.
Analysts covering IM Cannabis currently have a consensus Earnings Per Share (EPS) forecast of -CA$0.69 for the next financial year.
What is the trend in the IM Cannabis share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like IM Cannabis. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +0.06%.
As of the last closing price of CA$0.86, shares in IM Cannabis were trading +1.47% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the IM Cannabis PE Ratio?
The IM Cannabis PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.86.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of IM Cannabis?
IM Cannabis' management team is headed by:
- Marc Lustig - CHM
- Oren Shuster - CEO
- Shai Shemesh - CFO
- Richard Balla - CEX
- Yael Harrosh - COO
- Doron Reznick - OTH
- Haleli Barath - IND
- Vivian Bercovici - IND
- Brian Schinderle - IND